[HTML][HTML] Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease
P von Hundelshausen, W Siess - Cancers, 2021 - mdpi.com
Simple Summary Bruton tyrosine kinase (Btk) is expressed in B-lymphocytes, myeloid cells
and platelets. Since the launch of the first in class Btk-inhibitor (BTKi) ibrutinib in 2013, the …
and platelets. Since the launch of the first in class Btk-inhibitor (BTKi) ibrutinib in 2013, the …
[HTML][HTML] Btk inhibitors as first oral atherothrombosis-selective antiplatelet drugs?
K Busygina, V Denzinger, I Bernlochner… - Thrombosis and …, 2019 - thieme-connect.com
Bruton's tyrosine kinase (Btk) is essential for B cell differentiation and proliferation, but also
platelets express Btk. Patients with X-linked agammaglobulinemia due to hereditary Btk …
platelets express Btk. Patients with X-linked agammaglobulinemia due to hereditary Btk …
[HTML][HTML] Novel indications for Bruton's tyrosine kinase inhibitors, beyond hematological malignancies
R Campbell, G Chong, EA Hawkes - Journal of clinical medicine, 2018 - mdpi.com
Bruton's tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor
(BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell …
(BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell …
[HTML][HTML] Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an
effective therapeutic agent for multiple B‐cell‐mediated lymphoproliferative disorders …
effective therapeutic agent for multiple B‐cell‐mediated lymphoproliferative disorders …
Managing toxicities of Bruton tyrosine kinase inhibitors
A Lipsky, N Lamanna - Hematology 2014, the American Society …, 2020 - ashpublications.org
Inhibition of Bruton's tyrosine kinase (BTK) has revolutionized the treatment landscape for
patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal …
patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal …
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors
CPS Tang, J McMullen, C Tam - Leukemia & lymphoma, 2018 - Taylor & Francis
The development of bruton tyrosine kinase inhibitors (BTKi) has been a significant
advancement in the treatment of chronic lymphocytic leukemia and related B-cell …
advancement in the treatment of chronic lymphocytic leukemia and related B-cell …
[HTML][HTML] Bruton's tyrosine kinase inhibitors (Btkis): review of Preclinical studies and evaluation of clinical trials
D Rozkiewicz, JM Hermanowicz, I Kwiatkowska… - Molecules, 2023 - mdpi.com
In the last few decades, there has been a growing interest in Bruton's tyrosine kinase (BTK)
and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) …
and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) …
[HTML][HTML] BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
A Alu, H Lei, X Han, Y Wei, X Wei - Journal of Hematology & Oncology, 2022 - Springer
Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
[HTML][HTML] Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
PLR Nicolson, CE Hughes, S Watson, SH Nock… - …, 2018 - ncbi.nlm.nih.gov
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the
treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine …
treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine …
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans
The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has proven to be efficacious in the
treatment of B-cell chronic lymphocytic leukemia (B-CLL) and related diseases. However, a …
treatment of B-cell chronic lymphocytic leukemia (B-CLL) and related diseases. However, a …